Pharmaceutical company AbbVie announced Monday that it has reached an agreement to purchase biotech firm Apogee Therapeutics in an all-cash deal valued at $10.9 billion.
The acquisition is aimed at expanding AbbVie’s lineup of next-generation immunology treatments, according to the companies.
